234 related articles for article (PubMed ID: 25139038)
1. Balance of antiangiogenic and angiogenic factors in the context of the etiology of preeclampsia.
Seki H
Acta Obstet Gynecol Scand; 2014 Oct; 93(10):959-64. PubMed ID: 25139038
[TBL] [Abstract][Full Text] [Related]
2. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.
Saad AF; Kechichian T; Yin H; Sbrana E; Longo M; Wen M; Tamayo E; Hankins GD; Saade GR; Costantine MM
Reprod Sci; 2014 Jan; 21(1):138-45. PubMed ID: 23749761
[TBL] [Abstract][Full Text] [Related]
3. Angiogenic Imbalance as a Contributor of Preeclampsia.
Dymara-Konopka W; Laskowska M; Błażewicz A
Curr Pharm Biotechnol; 2018; 19(10):797-815. PubMed ID: 30255753
[TBL] [Abstract][Full Text] [Related]
4. Preeclampsia: new insights.
Shah DM
Curr Opin Nephrol Hypertens; 2007 May; 16(3):213-20. PubMed ID: 17420664
[TBL] [Abstract][Full Text] [Related]
5. Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion.
Tong S; Kaitu'u-Lino TJ; Onda K; Beard S; Hastie R; Binder NK; Cluver C; Tuohey L; Whitehead C; Brownfoot F; De Silva M; Hannan NJ
Hypertension; 2015 Nov; 66(5):1073-81. PubMed ID: 26324507
[TBL] [Abstract][Full Text] [Related]
6. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia.
Masuyama H; Nakatsukasa H; Takamoto N; Hiramatsu Y
J Clin Endocrinol Metab; 2007 Jul; 92(7):2672-9. PubMed ID: 17426083
[TBL] [Abstract][Full Text] [Related]
7. Placental-Specific sFLT-1 e15a Protein Is Increased in Preeclampsia, Antagonizes Vascular Endothelial Growth Factor Signaling, and Has Antiangiogenic Activity.
Palmer KR; Kaitu'u-Lino TJ; Hastie R; Hannan NJ; Ye L; Binder N; Cannon P; Tuohey L; Johns TG; Shub A; Tong S
Hypertension; 2015 Dec; 66(6):1251-9. PubMed ID: 26416849
[TBL] [Abstract][Full Text] [Related]
8. Maternal and foetal angiogenic imbalance in congenital heart defects.
Llurba E; Sánchez O; Ferrer Q; Nicolaides KH; Ruíz A; Domínguez C; Sánchez-de-Toledo J; García-García B; Soro G; Arévalo S; Goya M; Suy A; Pérez-Hoyos S; Alijotas-Reig J; Carreras E; Cabero L
Eur Heart J; 2014 Mar; 35(11):701-7. PubMed ID: 24159191
[TBL] [Abstract][Full Text] [Related]
9. Angiogenic factors in preeclampsia: so complex, so simple?
Berkane N; Lefevre G; Hertig A
Nephrol Dial Transplant; 2007 Oct; 22(10):2753-6. PubMed ID: 17617654
[No Abstract] [Full Text] [Related]
10. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
11. Biology of preeclampsia: Combined actions of angiogenic factors, their receptors and placental proteins.
Huppertz B
Biochim Biophys Acta Mol Basis Dis; 2020 Feb; 1866(2):165349. PubMed ID: 30553017
[TBL] [Abstract][Full Text] [Related]
12. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
Alahakoon TI; Zhang W; Trudinger BJ; Lee VW
J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
[TBL] [Abstract][Full Text] [Related]
13. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1.
Cudmore M; Ahmad S; Al-Ani B; Fujisawa T; Coxall H; Chudasama K; Devey LR; Wigmore SJ; Abbas A; Hewett PW; Ahmed A
Circulation; 2007 Apr; 115(13):1789-97. PubMed ID: 17389265
[TBL] [Abstract][Full Text] [Related]
14. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Nguyen TV; Tuohey L; Cluver C; Tong S; Kaitu'u-Lino TJ
Placenta; 2020 Jun; 95():78-83. PubMed ID: 32452405
[TBL] [Abstract][Full Text] [Related]
15. New developments in the pathogenesis of preeclampsia.
Naljayan MV; Karumanchi SA
Adv Chronic Kidney Dis; 2013 May; 20(3):265-70. PubMed ID: 23928392
[TBL] [Abstract][Full Text] [Related]
16. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.
Brownfoot FC; Tong S; Hannan NJ; Binder NK; Walker SP; Cannon P; Hastie R; Onda K; Kaitu'u-Lino TJ
Hypertension; 2015 Sep; 66(3):687-97; discussion 445. PubMed ID: 26222708
[TBL] [Abstract][Full Text] [Related]
17. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
[TBL] [Abstract][Full Text] [Related]
18. Circulating angiogenic factors and urinary prolactin as predictors of adverse outcomes in women with preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Ramírez-Valenzuela KL; Chinolla-Arellano ZL; Isordia-Salas I
Hypertension; 2013 May; 61(5):1118-25. PubMed ID: 23460287
[TBL] [Abstract][Full Text] [Related]
19. [New insights into the pathogenesis of pre-eclampsia: the role of angiogenesis-inhibiting factors].
Verdonk K; Visser W; Steegers EA; Kappers M; Danser AH; van den Meiracker AH
Ned Tijdschr Geneeskd; 2011; 155():A2946. PubMed ID: 21486506
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.
Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S
J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
